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Background and Objectives: Cancer services are under increasing pressure to deliver 
waiting time targets. Our service has seen referral numbers increase to over 3000 per annum, 
with more than 80% coming from secondary care. In order to deliver a responsive service, 
the department has introduced a daily diagnostic multidisciplinary meeting (DMDT) with the 
aim being stratification of resources by directing rapid access to clinics and diagnostics to 
those felt to be at greatest risk of malignancy at the start of the pathway. It also aimed to 
improve communication with patients and referrers, consistency in decision making and 
deliver improved diagnostic turn-around times in a sustainable manner. An evaluation was 
undertaken to assess whether the introduction of the DMDT has improved the pathway, the 
primary endpoint being a reduction in time to definitive diagnosis (TTDD). Secondary 
endpoints included measurements of efficiency and whether there has been a reduction in 
variation in practice.
Methods: Retrospective access to a prospective database over a 1-month period before 
(2015) and after (2018) the intervention.
Results: The introduction of the DMDT has led to a reduction in TTDD (7 days). The 
service also has an added benefit in reducing average total patient miles travelled over the 
course of diagnosis by 22.68 miles.
Conclusion: The introduction of a diagnostic MDT at the start of the pathway does lead to 
an improvement in service efficiency and a reduction in TTDD.
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Synopsis
An evaluation of our daily diagnostic multidisciplinary team meeting focusing on 
the improvement made to our diagnostic pathway and the overall impact on time to 
definitive diagnosis in the context of primary soft tissue and bone sarcoma.
Introduction
Multidisciplinary team (MDT) working has been the gold standard for care in all 
specialties since its introduction in the late 1990s. Before MDT meetings existed, 
there were large variations in clinical practice and the quality of reporting for 
radiological investigations and pathological specimens was poor.1 The Calman- 
Hine report2 was commissioned by the Government in the hope that regular 
MDT meetings would enhance the practice of evidence-based medicine and perso-
nalise care whilst preventing individuals from treating patients outside of accepted 
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standards. It also aimed to help reduce waiting times and 
improve the quality of care for patients with cancer; adher-
ing to the age-old principle that many hands make light 
work.1,3 Over the last 20 years, the cancer landscape has 
altered dramatically due to the increasing complexity of 
cases, ageing population and the increasing range of treat-
ment options available. Subsequently, cancer services in 
the UK are under heightened pressure to deliver on wait-
ing times. For clinicians, increased demand often means 
less time spent per case, especially where centres are 
involved in diagnostic services. This poses a substantial 
patient safety and quality risk and has called into question 
the value of the MDT meeting.4
Despite the widespread adoption of the MDT approach, 
the Cancer Waiting Times Annual Report published by 
NHS England highlights that services in the UK are con-
tinually falling short of the expected 85% standard when 
delivering on 62-day referral to treatment waiting times for 
all cancers, achieving a maximum of 82.4% since 2015.5–7 
A recent analysis carried out by the British Medical 
Association suggested that waiting times have deteriorated 
since the publication of the Annual Report stating that 
between January and February of 2019 almost a quarter 
of patients have had to wait more than 2 months for their 
first treatment after an urgent referral from their GP – only 
76.2% had their first treatment within the 62-day target, 
the worst performance against the set standard since it was 
introduced.8 Furthermore, cancer waiting times for diag-
nosis are set to decrease to 28 days as of April 2020, 
placing even more pressure on already stretched diagnostic 
services and making it even more important that our ser-
vices are streamlined and efficient.
Several recent papers have highlighted that although 
MDT meetings are now an integral part of mainstream 
cancer pathways and adherence to their use is high, they 
are costly and do not function as effectively as they 
should.2,9,10 The issues of cost and efficiency are highly 
relevant in the UK’s financially challenged, resource 
scarce climate today. De Iso et al identified a need to 
improve the efficiency both in terms of cost and time 
spent on MDT meetings without compromising, or 
worse, losing the considerable benefits of regular 
meetings.9 It has been suggested that a large proportion 
of cases reaching MDT meetings today do not require this 
level of discussion and time better used on more complex 
cases is wasted.2,9–12 This is corroborated by a study from 
Cancer Research UK, which highlighted that 75% MDT 
members agreed that some patients could be reviewed 
outside the MDT to enable more time for discussion of 
complex cases.11,13 Munro (2015) highlights that an aver-
age MDT will review between 15 and 30 patients per 
week, often repeating cases as more information and 
advice becomes available without progressing manage-
ment in a meaningful way. Furthermore, the paper sug-
gests that the MDT process consumes a disproportionate 
amount of the resources available for the care of patients 
with cancer.2
In light of these findings, the Cancer Transformation 
Board and the Department of Health carried out a project 
that aimed to reform MDT meetings to make them more 
effective in response to the increased demand. The project 
identified the need for a number of changes, including 
streamlining the current MDTs to make them more efficient 
and the need to return ownership and responsibility to indi-
viduals by giving them permission to make shared decisions 
with select patients without necessarily seeking approval 
from the MDT.14,15 Recommendation 38 from the 
Independent Cancer Taskforce Report agreed that the need 
to focus specialist time in MDT meetings on cases which do 
not follow established clinical pathways is a priority.15
Primary soft tissue and bone sarcomas are rare mesench-
ymal tumours which can arise almost anywhere in the body. 
On average, a general practitioner may only see one case of 
primary sarcoma in the entirety of their career. Their relative 
rarity and inherent heterogeneity make it difficult to develop 
steadfast guidelines for their diagnosis and management. 
Currently, the diagnosis and management of primary sarco-
mas is guided by advice published by the British Sarcoma 
Group.16–18 The key recommendation from the guidelines 
states that any patient with red flag symptoms should receive 
urgent imaging appropriate to the suspected pathology (plain 
radiograph for bone, ultrasound for soft tissue) and if this 
was inconclusive or suggestive of malignancy, should be 
referred to and reviewed by a specialist sarcoma MDT for 
further assessment.16–18 In a review of national figures, the 
bone sarcoma incidence rate has remained stable between 
1985 and 2009; however, the incidence rates of soft tissue 
sarcoma have risen by 26% between 1990 and 2007.19,20 At 
our institute, we have been running a weekly sarcoma MDT 
(WMDT) since 1993. The mean and maximum number of 
cases discussed at a single WMDT in 1993 were 15 and 31, 
respectively. In 2016, the mean and maximum number of 
cases reached 78 and 110, respectively, representing an 
overall increase of 420% and 255% since 1993.21 Our 
department, as a leading centre for orthopaedic oncology 
worldwide, now receives over 3000 referrals per annum, 
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with more than 80% of referrals coming from secondary 
care.
It was identified that this increase in WMDT discus-
sions was unsustainable, from both a work force and 
a decision-making perspective. A review of our processes 
showed opportunities to reduce waste, waiting times and 
variation in clinical practice as well as improve safety by 
changing the model of referral ownership. It further high-
lighted opportunities to focus resources by case stratifica-
tion, improve patient experience and at least meet, if not 
exceed the national target of 28 days for cancer diagnosis.
In order to deliver a responsive service, the department 
introduced a daily diagnostic MDT meeting (DMDT) in 2017 
alongside its weekly sarcoma MDT (WMDT). The DMDT 
employs a true multidisciplinary approach, much in the same 
way as the WMDT, involving a consultant orthopaedic oncol-
ogy surgeon, specialist consultant radiologist, clinical nurse 
specialist and an MDT coordinator as a minimum. It takes 
place daily (except for weekends) and is employed as a means 
of triaging the new referrals. All the findings, diagnostic 
decisions, and recommendations from the DMDT are directly 
entered into the patient’s records held within a prospective 
oncology database in real time. The cases are triaged into 
malignancy likely, malignancy possible, malignancy unlikely 
and malignancy excluded. This is in stark contrast to the 
review of referrals employed before the introduction of the 
DMDT, in which paper referrals were read by a single surgeon 
without direct input from a radiologist (Figures 1 and 2).
The objectives of the DMDT were to improve the 
pathway for our patients by stratifying resources and 
directing rapid access to diagnostics to those felt to be at 
greatest risk of malignancy at the start of the pathway. It 
also aimed to improve communication between clinicians 
and patients, to reduce the number of non-sarcoma cases 
discussed at the WMDT21 (thereby increasing cognitive 
bandwidth and time for discussion of complex cases) and 
to deliver clinical excellence in a patient centred, compas-
sionate manner. Lastly, it aimed to provide consistency in 
decision making and deliver improved diagnostic turn-
around times in a sustainable manner.
Aims
The aim of this evaluation is to assess whether the DMDT 
has improved the patient pathway, with the primary end-
points being a reduction in time to first management deci-
sion and a reduction in time to definitive diagnosis 
(TTDD). Secondary endpoints included measurements of 
the accuracy of the DMDT initial triage diagnosis com-
pared to the definitive diagnosis on histology and the 
ability of the DMDT to discharge patients without the 
need for the patient to travel to our centre.
Figure 1 A depiction of the referral process in 2015 before the introduction of the DMDT; illustrating the steps taken to appropriately triage the referral before making the 
first management decision. 
Abbreviation: MDT, multidisciplinary team meeting.
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Patients and Methods
All patients referred for a suspected bone or soft tissue 
malignancy were identified by interrogating our prospec-
tively maintained database. The search was conducted to 
include two time periods; the 1st to the 31st of January 
in both 2015 – before the introduction of the DMDT, 
and 2018 – after the introduction of the DMDT. 
Demographic data (Table 1) were collected along with 
time to triage the referral, time to a first management 
decision and provisional and final histological diagnosis 
(if a biopsy was performed) to determine overall accu-
racy of the DMDT triage.
Patients with a previous sarcoma diagnosis, cases 
designated “opinion only”, patients who withdrew from 
the diagnostic pathway for any reason, patients without 
data on the systems, patients deceased before formal 
diagnosis, patients related to the researchers and private 
patients were excluded from the study to give a cohort 
whose data reflected the whole diagnostic pathway within 
the public healthcare system.
101 consecutive patients met the inclusion criteria and 
were selected for the 2015 cohort and 135 consecutive 
patients were selected for the 2018 cohort. For both 
cohorts, the following data was collected.
● Date the referral was received and registered on our 
system
● Date the referral was triaged/seen at DMDT
● The provisional diagnosis ascribed at DMDT/triage
● Date the first management decision was made and 
what the decision was
● Date the definitive diagnosis was made
For both cohorts, the total number of days and the number 
of working days between dates were calculated using 
online date counting software.
A Fisher’s exact test was used to assess statistical signifi-
cance of a 2x2 contingency table in the analysis of the primary 
endpoint. A p value was calculated with two tails. An alpha 
value of 0.05 was considered statistically significant.
Figure 2 A depiction of the referral process in 2018 after the introduction of the DMDT; illustrating the steps taken to appropriately triage the referral and make a first 
management decision. 
Abbreviations: MDT, multidisciplinary team meeting; CNS, clinical nurse specialist; DMDT, diagnostic multidisciplinary team meeting.
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The service evaluation project on which this study was 
based was carried out with approval from our Clinical 
Audit and Effectiveness Team at our centre. Individual 
patient consent to access their medical records for the 
purpose of service evaluation was not required. The data 
were anonymised to maintain confidentiality and held 
securely in compliance with the Declaration of Helsinki.
Results
Primary Endpoints
Time to Triage/DMDT and First Management 
Decision
In 2015, on average, it took 2 total days for a referral to be 
triaged (median 1 day, range 1–22 days) and 11 total days 
to make a first management decision (median 8 days, 
range 1–124 days). In 2018, it took 3 total days to be 
seen at DMDT (median 3 days, range 1–22 days, an 
increase of 1 day p>0.05) and an average of 5 total days 
to make a first management decision (median 3 days, 
range 1–109 days, a reduction of 6 total days p>0.05).
No change in working time to triage was observed 
between 2015 and 2018. A reduction of 5 working days 
was observed in time to first management decision (med-
ian 2 days, range 1–76 days).
Time to Definitive Diagnosis
It took longer on average to diagnose the 2015 cohort than it 
did the 2018 cohort in terms of both total and working days.
Total Days to Definitive Diagnosis (TTDD) 
For all cases in 2015, the mean TTDD was 41 days 
(median 29 days, range 1–158 days). For all cases in 
2018, the mean TTDD was 34 days (median 28 days, 
range 2–152 days), a reduction of 7 days with the intro-
duction of the DMDT (p>0.05).
Working Days to Definitive Diagnosis (WTTD) 
For all cases in 2015, the mean WTTD was 29 days 
(median 21 days, range 1–109 days). For all cases in 
2018, the mean WTTD was 24 days (median 21 days, 
range 2–105 days), a reduction of 5 days with the intro-
duction of the DMDT (p>0.05).
Secondary Endpoints
Provisional Diagnosis at Triage/DMDT
No provisional diagnosis data were available for the 2015 
cohort as the single surgeon review of the referrals was not 
triaged into the categories used at the DMDT i.e malig-
nancy excluded, malignancy likely, malignancy possible 
and malignancy unlikely. For the 2018 cohort, provisional 
diagnosis was split into these four categories. Thirty cases 
were assigned “malignancy likely”, 34 cases were sub-
scribed “malignancy possible”, 27 cases were assigned 
“malignancy unlikely” and 44 cases had malignancy 
excluded based on history and imaging alone. Further 
information regarding the provisional diagnosis can be 
found in Table 2.
Table 1 Demographic Data for the 2015 and 2018 Cohorts
2015, N = 101 2018, N = 135
Age 95 Adults(94%) 6 Children(6%) 116 Adults(86%) 19 Children(14%)
Gender 47 Females(46%) 54 Males(54%) 67 Females(50%) 68 Males(50%)
Type of Referral 34 2WW(34%) 63 Routine(62%) 4 Urgent(4%) 29 2WW(21%) 100 Routine(74%) 6 Urgent(4%)
Referrer 69 Other Hospital Consultant(68%) 
32 GP(32%)
112 Other Hospital Consultant(83%) 
22 GP(16%) 
1 Allied Healthcare Professional(1%)
Pathway Used 29 Suspected Primary Bone Sarcoma(29%) 33 Suspected Primary Bone Sarcoma(24%)
46 Suspected Primary Soft Tissue Sarcoma(46%) 53 Suspected Primary Soft Tissue Sarcoma(40%)
26 Other Bone Pathology(25%) 49 Other Bone Pathology(36%)
Definitive Diagnosis 4 Primary Bone Sarcoma(4%) 3 Primary Bone Sarcoma(2%)
12 Primary Soft Tissue Sarcoma(12%) 11 Primary Soft Tissue Sarcoma(8%)
3 Haematological Malignancy(3%) 6 Haematological Malignancy(4%)
5 Metastatic Pathology(5%) 21 Metastatic Pathology(16%)
77 Benign (bone and soft tissue) Pathology(76%) 94 Benign (bone and soft tissue) Pathology(69%)
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Four of the cases in the “malignancy likely” group were 
proven benign after biopsy, 8 were proven to be malignant 
and 18 were proven to be metastatic. Of the “malignancy 
possible” group, 4 were metastatic disease, 19 were benign 
and 11 were found to be malignant. Of the “malignancy 
unlikely” group, all 27 were found to be benign.
Measurement of Accuracy of Triage/DMDT
No provisional diagnoses were assigned in 2015 therefore 
we were unable to measure the accuracy of the single 
surgeon triage. Sensitivity of the DMDT was found to be 
100% (95% CI 91.4% - 100%). Specificity was found to 
be 54% (95% CI 36.44% - 57.39%). Fifty cases ascribed 
a more sinister provisional diagnosis were downgraded to 
benign pathologies after biopsy. No cases ascribed 
a malignancy excluded provisional diagnosis were subse-
quently found to be malignant.
Outcomes of the First Management Decision
The outcomes of the first management decisions made in 
2015 and 2018 are detailed in Tables 3 and 4 respectively. 
“Surgery” denotes excision of the lesion in theatre. 
“Clinic” denotes seen in a specialist orthopaedic oncology 
clinic by a consultant or registrar. “Biopsy” denotes the 
procurement of a tissue sample by accepted means (CT or 
USS guided) without complete excision.
Impact on Distance Travelled
The accuracy of the DMDT means that in 2018, 24% of 
patients are discharged at the point of triage removing the 
need to travel to our centre. Patients travelled on average 
a total of 172.94 miles over the course of their diagnosis in 
2015 (median 80 miles, range 1–368 miles). With the intro-
duction of the DMDT patients travelled on average a total of 
150.26 miles over the course of their diagnosis (median 68 
miles, range 1–489 miles). This represents a reduction in 
patient miles travelled of 22.68 miles (p<0.05).
Discussion
Statement of Principle Findings
Our study has shown that the introduction of the DMDT 
has reduced our time to make a first management decision 
by 6 total days and our time to definitive diagnosis by 7 
total days.
As a result of the introduction of the DMDT, 24% of 
patients were discharged from our service without having 
to travel to our centre (Table 4), saving an average of 
22.68 miles over the course of their diagnosis (p<0.05) 
despite our catchment area expanding. The sensitivity and 
specificity of the DMDT further corroborate the accuracy 
of the triaging system. We have not seen any of the 24% of 
discharged patients (all with benign diagnoses) re-referred 
for further management or with a deteriorating clinical 
picture necessitating a change in diagnosis to a more sin-
ister pathology.
We have also demonstrated an increase in the schedul-
ing of multiple diagnostic techniques at the point of triage 
as a result of the introduction of the DMDT (11% in 2018 
compared to 1% in 2015) with a subsequent reduction in 
the scheduling of each of the single diagnostic services 
(biopsy only 21% in 2015–3% in 2018, clinic only 18% in 
2015–13% in 2018 and scan only 7% in 2015–1.5% in 
Table 2 Provisional Diagnosis at DMDT Data (2018)
Group Sub-Group Number of Cases
Malignancy Likely (N = 30) Sarcoma Malignancy (Bone/STS) 15
Non-Sarcoma Malignancy (Metastatic Disease/Pathological Fracture) 15
Malignancy Possible (N = 34) Sarcoma Malignancy (Bone/STS) 32
Non-Sarcoma Malignancy (Metastatic Disease/Pathological Fracture) 2
Malignancy Unlikely (N = 27)
Malignancy Excluded (N = 44)
Table 3 Outcomes of First Management Decision (2015)
Clinic Only 18% Clinic + Scan + Biopsy 1%
Biopsy Only 21% Scan + Biopsy 10%
Scan Only 7% Discharge 18%
Clinic + Scan 16% Palliative 0%
Clinic + Biopsy 6% Surgery 4%
Table 4 Outcomes of First Management Decision (2018)
Clinic Only 13% Clinic + Scan + Biopsy 11%
Biopsy Only 3% Scan + Biopsy 1.5%
Scan Only 1.5% Discharge 24%
Clinic + Scan 19% Palliative 1.5%
Clinic + Biopsy 24% Surgery 1.5%
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2018) highlighting our “one-stop shop” approach and 
hence, the increased efficiency of our service. We antici-
pate a further improvement in efficiency as the system 
matures. Further studies are ongoing to identify subse-
quent inefficiencies in the pathway which prevent us 
from reaching the national diagnostic target of 28 days.
Relevance to Clinical Practice
Subjectively, for the patient, nothing is more important 
than receiving a diagnosis and initiating management in 
an expedient and stress-free manner,22–27 especially in 
the context of cancer. The new Cancer Waiting Time 
Targets reflect this – the drive to diagnose patients and 
initiate treatment within 28 days puts added pressure on 
already overworked diagnostic centres but is inherently 
patient centred. Awaiting diagnosis and treatment has 
been cited as one of the most stressful experiences for 
patients in today’s NHS, regardless of the nature of the 
potential diagnosis.27–30 The reduction in TTDD of 7 
total days suggests that the use of a DMDT may be 
a reproducible way of reducing diagnostic turnaround 
times, helping us to meet the nationally mandated wait-
ing time targets and reduce patient anxiety. Additionally, 
financial compensation for meeting targets incentivises 
services to accelerate diagnosis and treatment initiation. 
The financial implications of implementing such 
a service are outside the scope of this study and further 
research is needed.
We have not directly looked at the psychological 
impact of our DMDT on our patients beyond informal 
interviews where patients and carers have reported a high 
level of satisfaction with the service. However, we antici-
pate that it has had a positive effect. The DMDT affords us 
the ability to give patients an almost immediate provi-
sional diagnosis and management plan as well as provide 
psychosocial support from Clinical Nurse Specialists. 
Furthermore, feedback to referring clinicians is delivered 
on the same day as the DMDT and our protocols dictate 
that routine referrals triaged as “malignancy likely” are 
upgraded onto a cancer pathway thereby further ensuring 
prompt progression along the clinical pathway, minimizing 
delays.
Aside from the psychological impact, we know from 
studies done in cancer settings in general that rapid diag-
nosis and treatment also has an impact on the clinical 
outcome.20,22,28,29 Rarer cancers tend to be more advanced 
at presentation to diagnostic services and as such have 
poorer outcomes.31 Management of advanced cancers has 
also been shown to be more complex than those presenting 
early.28,29 Similarly, the overall mortality and morbidity of 
more advanced cancers has been shown to be higher.22,32 
It, therefore, follows that the sooner the diagnosis is made, 
in our case – 7 days earlier, the sooner treatment can be 
initiated and the better the potential outcome for the 
patient; however, we currently have no data to support 
this.
Despite incentives for meeting nationally imposed tar-
gets, our NHS is perpetually financially limited. Therefore, 
it is important that we use our limited resources in an 
efficient manner, directing them to those most in need. 
Our study has shown that nearly a quarter of patients are 
discharged from our service without the need to travel to 
our centre (Table 4). The “one-stop shop” approach to 
diagnostics (first proposed in Chang et al in 199824) 
means faster access to clinic appointments, biopsies and 
scans for those felt to be at greatest risk at the start of the 
pathway. Additionally, it means unacceptable delay 
imposed by employing single diagnostic services in 
a sequential manner is mitigated. Furthermore, although 
not directly studied in this paper, the DMDT can improve 
the efficiency of the weekly sarcoma MDT as cases have 
been stream-lined prior to being added to the discussion 
list, meaning greater cognitive bandwidth is available to 
discuss more complex patients.
Limitations
Our study was conducted in a high volume, tertiary centre 
for bone and soft tissue sarcoma. As a result, the popula-
tion studied is niche and small meaning wider generalisa-
bility could be lost. Bone and soft tissue sarcomas are 
inherently rare conditions which, for the majority of clin-
icians, may never be encountered in everyday practice. 
There are 5 centres in England that provide diagnostic 
services for suspected bone sarcoma – we believe our 
data are demographically similar to that of the wider 
sarcoma population and could be extrapolated and applied 
to their populations despite the small sample size. One 
could argue that this methodology is also well suited to 
other image-based diagnostic conditions, eg, neurological, 
liver and lung cancers and since the number of referrals for 
these cancers is greater than that of sarcoma, the impact of 
frequent diagnostic MDTs (outside of formal cancer 
MDTs) may be larger.
Efforts have been made to reduce selection bias by 
selecting the same time period (January) for both cohorts. 
This was to mitigate the impact the time of year may have 
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had on the number of cases triaged at our centre. Provider 
availability in 2015 may also have affected our results - in 
particular, time to first management decision. Our analysis 
could be strengthened by selecting two cohorts from dif-
ferent months to mitigate this. However, as we now pro-
vide an adequately staffed year-round service, we 
anticipate that this would have little impact on the 
findings.
Lastly, this study has not assessed the psychological 
impact and clinical outcomes of these patients; however, 
we anticipate that a faster triage process and an earlier 
diagnosis following the introduction of the DMDT has had 
a positive impact on these outcomes. Further studies are 
required to assess the impact of earlier diagnosis on long- 
term outcomes.
Conclusion
This pioneering measure of introducing a DMDT has 
multiple benefits. The daily diagnostic MDT has reduced 
our overall time to definitive diagnosis. The DMDT 
ensures all new referrals receive a prompt, consistent 
opinion, which can be fed back directly to the patients 
and referring clinicians. In particular, 24% of patients 
were discharged without the need for them to travel to 
our department. As the April 2020 deadline for the intro-
duction of the new cancer waiting times target comes into 
force, the ability to risk stratify and direct resources 
appropriately becomes ever more important. The imple-
mentation of this DMDT model requires the engagement 
and collaboration of the whole MDT and wider hospital 
management in order to achieve and embed these bene-
fits. However, we propose that our DMDT is 
a reproducible model that can be employed in other 
cancer services involved in both the diagnosis and treat-
ment of patients with the aim of reducing time to defini-
tive diagnosis, directing resources, and improving the 
patient pathway.
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